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Abstract
Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B cell development and function. We have
previously shown that IRF4, together with IRF8, orchestrates pre-B cell development by limiting pre-B cell expansion and by
promoting pre-B cell differentiation. Here, we report that IRF4 suppresses c-Myc induced leukemia in EmMyc mice. Our
results show that c-Myc induced leukemia was greatly accelerated in the IRF4 heterozygous mice (IRF4
+/2Myc); the average
age of mortality in the IRF4
+/2Myc mice was only 7 to 8 weeks but was 20 weeks in the control mice. Our results show that
IRF4
+/2Myc leukemic cells were derived from large pre-B cells and were hyperproliferative and resistant to apoptosis.
Further analysis revealed that the majority of IRF4
+/2Myc leukemic cells inactivated the wild-type IRF4 allele and contained
defects in Arf-p53 tumor suppressor pathway. p27
kip is part of the molecular circuitry that controls pre-B cell expansion. Our
results show that expression of p27
kip was lost in the IRF4
+/2Myc leukemic cells and reconstitution of IRF4 expression in
those cells induced p27
kip and inhibited their expansion. Thus, IRF4 functions as a classical tumor suppressor to inhibit c-
Myc induced B cell leukemia in EmMyc mice.
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Introduction
B cell development features a sequential rearrangement of
immunoglobulin heavy and light chain loci and expression of dis-
tinct cell surface markers [1]. After productive heavy chain
rearragment at the pro-B stage, the newly synthesized heavy chain
pairs with surrogate light chains and forms the pre-B cell receptor
(pre-BCR). Pre-B cells consist of two distinct subsets: large pre-B and
small pre-B cells. Large pre-B cells are cycling cells expressing pre-
BCR whereas small pre-B cells are quiescent cells following cell cycle
exit. Pre-B cells expansion and the subsequent transition from large
pre-B to small pre-B cells are tightly regulated during B cell
development and is dependent on signals from the pre-BCR and IL-
7 receptor [2]. Disruption of this coordinated developmental process
can lead to abnormal B cells development and transformation.
Indeed, acute lymphoblast leukemia (ALL) is often derived from pre-
B cells that exhibit defects in proliferation and differentiation [3].
Interferon regulatory factor 4 (IRF4), is expressed predomi-
nantly in the immune system and plays an important role in its
development and function [4]. IRF4, together with IRF8, are
critical for the pre-B cell development. In the absence of IRF4 and
IRF8, B cell development is blocked at the large pre-B stage [5].
We have shown that IRF4 limits pre-B cell expansion by inducing
Ikaros and Aiolos which in turn directly suppress c-Myc expression
[6,7]. In addition, IRF4 is critical for light chain rearrangement
and receptor editing [8,9,10]. Beside its role at the pre-B stage,
IRF4 is also required for mature B cell function. It has been shown
that mice lacking IRF4 (IRF4
2/2) fail to generate plasma cells and
are defective in response to T cell dependent and independent
antigens [11]. Recent studies have further shown that IRF4 is
critical for the class-switch recombination by inducing activation
induced deaminase (AID) and for germinal center reaction by
downregulating Bcl6 [12,13,14]. IRF4 has been found to induce
c-Myc expression in multiple myeloma cells and is critical for their
survival and expansion [15]. Finally, IRF4 can induce the
expression of Fas apoptosis inhibitory molecule (FAIM) to regulate
mature B cell survival and apoptosis [16].
Given its role as a critical transcriptional regulator that limits
pre-B cell expansion and promotes pre-B cell differentiation, it is
reasonable to assume that IRF4 may function as a tumor
suppressor against pre-B cell transformation. Indeed, a previous
study has shown that IRF4 functions as a tumor suppressor to
inhibit BCR/ABL oncogene induced B cell acute lymphoblastic
leukemia (B-ALL) [17]. In addition, mice deficient for both IRF4
and IRF8 develop lymphoblastic leukemia [18]. Although IRF4
can suppress BCR/ABL induced B cell transformation, the
molecular mechanism by which IRF4 exerts its function remains
unclear. In this report, we assessed the role of IRF4 in c-Myc
oncogene induced B cell transformation by breeding IRF4
deficient mice with EmMyc transgenic mice. In the EmMyc mice,
the expression of c-Myc oncogene is driven by immunoglobulin
heavy chain enhancers and is predominantly found in the B cells.
EmMyc transgenic mice mainly develop two types of leukemia/
lymphoma: pro/pre-B derived and mature B cell derived and the
majority of the EmMyc mice succumb to disease within 5 to 6
months of age [19]. It has been shown that the leukemogenesis of
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suppressor genes and thus, EmMyc mice have been widely used
as an animal model to assess the role of potential oncogenes or
tumor suppressor genes in B cell transformation [20,21,22,23].
In this report, we show that c-Myc induced leukemia was
greatly accelerated in the IRF4 heterozygous mutant mice.
Moreover, we provided evidence that IRF4 functions as a classical
tumor suppressor gene to inhibit c-Myc induced leukemogenesis.
Our results further revealed that deficiency of IRF4 accelerated
the loss of p27
kip in the EmMyc mice and reconstitution of IRF4
expression in leukemic cells restored p27
kip expression in leukemic
cells and inhibited their proliferation in vivo.
Results
C-Myc induced leukemia was accelerated in the IRF4
+/2
Myc mice
We did not observe a significant increase in tumor formation in
IRF4 deficient mice, indicating that deficiency for IRF4 alone isn’t
sufficient for tumor development. Here, we wanted to examine
whether deficiency of IRF4 synergizes with the c-Myc oncogene to
induce B cell leukemia and lymphoma. We crossed IRF4
2/2 mice
with the EmMyc mice and generated IRF4 heterozygous mutant
mice expressing EmMyc transgene (IRF4
+/2Myc). To our surprise,
IRF4
+/2Myc miceshowed a dramatically accelerated mortality with
a median age of7 to 8 weeks (Fig. 1A). In contrast, the medianage of
mortality for IRF4
+/+Myc mice is 20 weeks (Fig. 1A). By five weeks
of age, IRF4
+/2Myc mice had already massively enlarged spleens,
while this was not evident in the IRF4
+/+Myc mice of the same age
(Figure S1A). H&E staining of isolated spleens further shows that
while the demarcation of white and red pulps is clearly discernible in
IRF4
+/2 and IRF4
+/+Myc mice, it disappeared in the IRF4
+/2Myc
mice due to the expansion and infiltration of leukemic cells.
FACS analysis of cells in the bone marrow and spleen further
show that there was a massive expansion of B220+ B cells in
the IRF4
+/2Myc mice (Fig. 1C/D and Tab. 1/2). Compared to
IRF4
+/+Myc mice, the absolute numbers of B220+ B cells was
found to be 3-fold higher in bone marrow and 10-fold higher in
spleen. While the absolute numbers of B220+IgM+ B cells in bone
marrow and spleen were comparable between IRF4
+/+Myc and
IRF4
+/2Myc mice, the absolute numbers of B220+IgM2 B cells
were dramatically increased in the IRF4
+/2Myc mice (Fig. 1C/D
and Tab 1/2).The massive expansion of leukemic cells also severely
affected the development of other blood lineages. As shown in
Fig. 1C, the percentages of CD11b+ myeloid cells in bone marrow
decreased from 32% in the IRF4
+/+Myc mice to only 1% in the
IRF4
+/2Myc mice. In spleen, the percentage of Thy1+ T cells
decreased from 21% in IRF4
+/+Myc mice to only 3% in the
IRF4
+/2Myc mice. The expansion and infiltration of leukemic cells
also caused severe erosion and thinning of the femus and tibia. In
addition, the B cell population (mainly B220+IgM2) was also
increased in the blood of IRF4
+/2Myc mice (Fig. 1E and data not
shown). The leukemic cells also infiltrated the lymph node, Thymus
andliver,resultinginmildtomoderateenlargementofthoseorgans.
Two additional sets of independent analysis can be found in Figure
S1. Collectively, our results indicate that the IRF4
+/2Myc mice
developed leukemia that originated from B cell progenitors.
IRF4
+/2Myc leukemic cells were derived from large pre-B
cells and were transplantable
To determine the identity of B220+IgM2 cells in the
IRF4
+/2Myc mice, we stained the cells with a panel of cell
surface as well as intracellular markers such as CD43, Bp-1,
intracellular mu and surrogate light chain l5. Pre-B cells express
Bp-1 but do not express CD43. The heavy chain protein mu (m)
can be detected intracellularly in the pre-B but not the pro-B cells.
l5 is a component of pre-B cell receptor found only on the cell
surface of pre-B cells. FACS analysis showed that B220+IgM2
leukemic cells in the IRF4
+/2Myc mice did not express CD43 but
express a high level of Bp-1, intracellular m and surrogate light
chain l5 (Fig. 2A/B/C/D). Collectively, these results indicate that
the B220+IgM2 leukemic cells were derived from the large pre-B
cells. To determine if the leukemic cells derived from IRF4
+/2Myc
mice are transplantable, we injected IRF4
+/2Myc bone marrow
cells into non-irradiated wild type syngenic host mice. All ten
recipient mice developed leukemia similar to IRF4
+/2Myc mice
(Fig. 2E) and died within two month of transplantation. Two
additional sets of independent analysis can be found in Figure S2.
In summary, IRF4
+/2Myc mice develop pre-B cells derived
leukemia that is transplantable in the syngenic mice.
The B220+IgM2 cells in IRF4
+/2Myc mice exhibited
enhanced proliferation and reduced apoptosis
We wanted to identify the molecular defects that led to the
accelerated leukemogenesis in the IRF4
+/2Myc mice. To this end,
we examined the survival and proliferation of B220+IgM2 cells in
the bone marrow of 4-weeks old IRF4
+/2Myc mice prior to the
development of symptoms. At this age, although there was
expansion of B220+IgM2 cells in the bone marrow and spleen of
IRF4
+/2Myc mice, there were few B220+IgM2 cells in the blood
(data not shown). Bone marrow cells were isolated from IRF4
+/2,
IRF4
+/+Myc and IRF4
+/2Myc mice. After surface staining, the cell
cycle status of B220+IgM2 cells was examined with Hoechst dye as
previously described [6,7]. Compared to the IRF4
+/+Myc mice,
B220+IgM2 cells in the IRF4
+/2 Myc mice were hyperprolifera-
tive as 3868% of B220+IgM2 cells were cycling (in S and G2/M
phases) in the IRF4
+/2Myc mice compared to 3066% in the
IRF4
+/+Myc mice (Fig. 3A). BrdU pulse-labeling analysis further
revealed that the B220+IgM2 cells in IRF4
+/2 Myc mice were
cycling faster than their counterparts in the IRF4
+/+Myc mice (data
not shown). TUNEL analysis further revealed that 4.861.1% of
B220+IgM2 cells in the IRF4
+/+Myc mice were apoptotic whereas
only 1.260.6% of them in the IRF4
+/2Myc mice underwent
apoptosis (Fig. 3B). Collectively, these results show that the
expanded B220+IgM2 cells in the IRF4
+/2Myc mice are
hyperproliferative and resistant to apoptosis.
Loss the expression of p27
kip and disruption of the Arf-
p53 pathway in the IRF4
+/2Myc leukemic cells
P27
kip is a cell cycle inhibitor, and loss of p27
Kip expression has
been shown to accelerate c-Myc induced leukemia and lymphoma
[23]. Moreover, our previous study has shown that p27
kip is part of
molecular circuitry that is responsible for shutting down pre-B cell
proliferation [6]. Here, we further examined the expression of
p27
kip in the B220+IgM2 cells described in Fig. 3A. Although
p27
kip expression was readily detectable in all three IRF4
+/+Myc
cells, its expression was lost in all six IRF4
+/2 Myc cells (Fig. 4A).
Importantly, expression of c-Myc was comparable between
IRF4
+/+Myc and IRF4
+/2Myc cells (Fig. 4A). To further assess
the role of p27
kip in the proliferation of IRF4
+/2Myc leukemic cells,
we transduced cultured IRF4
+/2Myc leukemic cells with p27
kip
expression plasmid. As shown in Fig. 4B, restoring the expression of
p27
kip dramatically inhibited the proliferation of IRF4
+/2Myc
leukemic cells. The percentage of cycling cells decreased from 35%
in the control to 12% in the p27
kip transduced cells. Collectively,
these results suggest that defective expression of p27
kip contributes
to the hyperproliferative index of IRF4
+/2Myc leukemic cells.
IRF4 Suppresses c-Myc Induced Leukemia
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dependent on the disruption of Arf-p53 tumor suppressor pathway
[24,25]. It has been shown that p53 is frequently mutated in EmMyc
tumor [24]. The mutant form of p53 is often overexpressed and
functions as a dominant negative mutant. To determine if Arf-p53
pathway is disrupted in the IRF4
+/2Myc leukemic cells, we
measured the expression of p53, Arf and c-Myc in IRF4
+/2
leukemic cells isolated from twelve different diseased mice. Our
results show that p53 was overexpressed in three IRF4
+/2Myc
leukemic cells (Fig. 4C). Further sequence analysis shows that all
three cells contained a p53 misense mutation R270C, which
corresponds witha mutation hotspot of p53 found in human tumors
[26]. Expression of Arf is transcriptionally suppressed by p53 and
the loss of p53 function often lead to overexpression of Arf in
EmMyc tumor cells. Indeed, Arf was overexpressed in IRF4
+/2Myc
leukemic cells expressing mutant p53 (Fig. 4C). Overall, three out of
twelve IRF4
+/2Myc clones expressed mutant p53, a frequency that
is similar to what has been reported in wild type EmMyc mice [24].
IRF4 functions as a tumor suppressor in c-Myc induced
leukemia
The finding that c-Myc induced leukemia was dramatically
accelerated in the IRF4
+/2 mice indicates that IRF4 functions as a
tumor suppressor in c-Myc induced leukemia. During tumorigen-
Figure 1. c-Myc induced leukemia was accelerated in the IRF4
+/2 Myc mice. A). Kaplan-Meier survival curve of IRF4
+/2, IRF4
+/+Myc and
IRF4
+/2Myc mice. The genotypes and numbers of mice in each group are indicated on the plot. P value for pair-wise comparison using log rank test
between IRF4
+/+Myc and IRF4
+/2Myc is p,0.0001. Graphpad PRISM 5.03 (Graphpad Software Inc) was used to plot the survival curve and calculate p
value. B) Spleens were isolated from IRF4
+/2, IRF4
+/+Myc and IRF4
+/2Myc mice and paraffin-embedded for H&E staining analysis. The stained tissues
were examined under both low (2.56) and high (106) magnifications. C/D/E). Cells were isolated from the bone marrow (C), spleen (D) and blood (E)
of six-week old IRF4
+/2, IRF4
+/+Myc and IRF4
+/2Myc mice, stained with indicated antibodies and analyzed by FACS. Numbers indicated the
percentages of cells in the respective quadrant. CD11b+ myeloid cells in the bone marrow were examined under a live cell gate while B and T cells
were examined under a lymphocyte gate. The data shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0022628.g001
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inactivation of the second allele. Indeed, in IRF4
+/2Myc leukemic
cells, the expression of IRF4 is loss in five out of six IRF4
+/2Myc
leukemic cells examined (Fig. 5A). Further sequence analysis of
mRNA and DNA did not reveal deletion or mutations of
IRF4 gene, suggesting that loss of IRF4 expression in the
IRF4
+/2Myc leukemic cells could be mediated by an epigenetic
event or by the loss of essential transcriptional regulators. In
contrast, the expression of c-Myc was not significantly affected in
the IRF4
+/2Myc leukemic cells.
To further examine the effect of IRF4 on c-Myc induced
leukemogenesis, we developed a doxycycline (Dox) inducible,
bitransgenic mouse model system in which the expression of
IRF4 can be regulated in vivo by Dox. The first transgenic line
MMTV-tTA was developed by Hennighausen et al, in which the
expression of the tetracycline transactivator gene (tTA) is driven by
the mouse mammary tumor virus LTR [27]. In this system, the
tTA is active in the absence but not in the presence of Dox.
Interestingly, it has been demonstrated that the tTA is expressed at
a high level in the B cells of MMTV-tTA mice and thus, this
model has been successfully used to induce B cell specific transgene
expression [28,29,30,31]. As shown in Fig. 5B, expression of the
IRF4 transgene is driven by a TRE promoter which consists of a
minimal CMV promoter linked to tetracycline response elements.
IRF4Tg and MMTV-tTA transgenic mice were crossed to
generate double transgenic mice that are hemizygous for IRF4Tg
and MMTV-tTA (Tg-tTA). The mice were initially fed with a
high concentration of Dox (2 mg/ml Dox, 4% sucrose) for couple
days and then switched to a low concentration to keep the
transgene inactive. The expression of the IRF4 transgene was
induced in mice by switching them to regular water. To examine
the expression pattern of the IRF4 transgene in immune cells, we
isolated B cell (B220+), granulocytes (Gr1+), and CD4+ T cells
from bone marrow and spleen of Tg-tTA mice. Expression of the
IRF4 transgene was detected with an anti-HA antibody. As shown
in Fig. 5C, the IRF4 transgene was predominantly expressed in the
B cells in the absence of Dox.
The Tg-tTA transgenic mice were subsequently crossed with
IRF4 deficient mice and EmMyc mice to generate triple transgenic
mice in the IRF4 heterozygous background (IRF4
+/2MycTg-
tTA). At five weeks of age, IRF4
+/2MycTg-tTA mice were either
switched to regular water to induce transgene expression or
continuously fed with dox water. After another three weeks, the
mice were sacrificed and analyzed. The total number of
B220+IgM2 B cells was dramatically reduced in the bone
marrow and spleens of IRF4
+/2MycTg-tTA mice fed with regular
water (Fig. 5D and data not shown), indicating that expression of
IRF4 transgene inhibited the expansion of IRF4
+/2Myc leukemic
cells. Cell cycle analysis further shows that expression of IRF4
transgene inhibited the proliferation of IRF4
+/2Myc cells (Fig. 5E).
Western blot analysis revealed that expression of p27
kip was
elevated in the IRF4
+/2Myc cells expressing IRF4 transgene.
Collectively, these results indicate that reconstitution of
IRF4 expression induces p27
kip and inhibits the proliferation of
IRF4
+/2Myc leukemic cells.
Discussion
In this report, we provide evidence that IRF4 functions as a
tumor suppressor in c-Myc induced B cell leukemia. Our results
show that c-Myc induced leukemia was dramatically accelerated in
IRF4
+/2Myc mice. Moreover, five out of six of IRF4
+/2Myc
leukemic clones further inactivated the remaining wild type IRF4
allele, resulting in a complete loss of IRF4 expression in those cells.
Our finding is consistent with a previous study which shows that
IRF4 functions as tumor suppressor in BCR/ABL oncogene
induced B-ALL and further demonstrates that IRF4 is capable of
functioning as a tumor suppressor against a broad spectrum of
oncogene insults at the pre-B stage. The accelerated leukemogen-
esis in the IRF4+/2Myc mice can be caused by defect in pre-B
cell development. Progenitor B cells are expanded in wild type
EmMyc mice. As IRF4 is a critical regulator of pre-B cell
differentiation, loss of IRF4 expression can further exacerbate the
defect in early B cell development in the EmMyc mice, causing
further expansion of progenitor B cells pool that could serve as
targets for subsequent transformation.
C-Myc induced leukemia and lymphoma is held in check by
p27
kip which inhibit cell cycle progression and by the Arf-p53
pathway that promotes apoptosis [20,24,32]. However, the
frequency of p53 mutation in the IRF4
+/2Myc leukemic cells is
similar to wild type EmMyc cells, suggesting that accelerated
leukemogenesis in IRF4
+/2Myc mice isn’t a result of high
frequency of p53 mutation. Instead, our results indicate that
deficiency of IRF4 accelerates the loss of p27
kip in c-Myc
overexpressing cells. First, the expanded B220+IgM-cells in
IRF4
+/2Myc mice lost the expression of p27
kip and were
hyperproliferative; second, reconstitution of IRF4 expression in
IRF4
+/2Myc leukemic cells induced the expression of p27
kip and
Table 1. Absolute number of B220+, B220+IgM2 and
B220+IgM+ B cells in bone marrow of IRF4+/+, IRF4+/2,
IRF4+/+Myc and IRF4+/2Myc mice (610
6).
Genotype B220+ B220+IgM2 B220+IgM+
IRF4+/+ 3.862.1 2.561.4 1.360.6
IRF4+/2 3.160.7 1.960.6 1.060.2
IRF4+/+Myc 6.162.3 5.162.7 1.060.1
IRF4+/2Myc 19.566.4** 18.065.7** 1.360.4
Total number of B220+, B220+IgM2 and B220+IgM+ B cells in mice of different
genotypes under study. Cell were isolated from bone marrow of five-week- old
IRF4+/+,I R F 4 +/2 IRF4+/+Myc and IRF4+/2Myc mice. The cells were stained
with antibodies against B220 and IgM and analyzed by FACS. The numbers are
the averages and standard deviations of the results for a total of five mice in
each group.
**p,0.01 (compared to their counterparts in the IRF4+/+Myc mice).
doi:10.1371/journal.pone.0022628.t001
Table 2. Absolute number of B220+, B220+IgM2 and
B220+IgM+ B cells in spleen of IRF4+/+, IRF4+/2, IRF4+/+Myc
and IRF4+/2Myc mice (610
6).
Genotype B220+ B220+IgM2 B220+IgM+
IRF4+/+ 29.7613.5 0.960.4 29.6612.5
IRF4+/2 15.066.2 0.560.4 14.765.8
IRF4+/+Myc 14.767.8 0.660.3 14.368.0
IRF4+/2Myc 141.0648.0** 128.0640.4** 12.767.8
Total number of B220+, B220+IgM2 and B220+IgM+ B cells in mice of different
genotypes under study. Cell were isolated from spleen of five-week- old IRF4+/+,
IRF4+/2 IRF4+/+Myc and IRF4+/2Myc mice. The cells were stained with antibo-
dies against B220 and IgM and analyzed by FACS. The numbers are the averages
and standard deviations of the results for a total of five mice in each group.
**p,0.01 (compared to their counterparts in the IRF4+/+Myc mice).
doi:10.1371/journal.pone.0022628.t002
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induce the expression p27
kip in leukemic cells [33]. As expression
of Ikaros is induced by IRF4, it is possible that the induction of
p27
kip expression could be mediated by Ikaros. It is also possible
that loss of IRF4 expression somehow accelerates the loss of p27
kip
in c-Myc overexpressing cells through mechanisms independent of
Ikaros.
Pre-B cell receptor signaling has been proposed as a guardian of
pre-B cell transformation by coordinating pre-B cell expansion
and differentiation. IRF4 expression is dependent on pre-BCR
signaling which is transduced by downstream signaling molecules
such as Blnk, Btk and PLCc2. Moreover, previous studies have
identified Btk, Blnk and PLCc2 as potential tumor suppressors
against pre-B cell transformation [34,35,36,37]. Interestingly, a
previous study has shown that c-Myc induced leukemia/lymp-
homa is accelerated in PLCc2 deficient mice (PLCc2
2/2Myc)
[34]. Similar to IRF4, PLCc2 is critical for pre-B cell development
and in its absence, pre-B cell development is partially blocked,
resulting in an expansion of pre-B cells. Interestingly, like
IRF4
+/2Myc leukemic cells, PLCc2
2/2Myc tumor cells lost the
expression of p27
kip and didn’t exhibit enhanced frequency of p53
mutation [34]. However, PLCc2 does not behave like classical
tumor suppressor as c-Myc induced leukemogenesis remains unal-
tered in the PLCc2
+/2Myc mice. In contrast, our results show that
IRF4 behaves like a classical tumor suppressor, downstream of
pre-BCR signaling, that functions to inhibit c-Myc induced
leukemia.
Materials and Methods
Mice
IRF4 mutant mice (IRF4
2/2) have been previously described
[11]. EmMyc transgenic mice were purchased from Jackson
Laboratories [19]. EmMyc transgenic mice were bred with
IRF4
2/2 mice to generate IRF4
+/2 mice that are hemizygous
for Myc transgene (IRF4
+/2Myc). All mice were maintained
under specific pathogen-free conditions. Experiments were
performed according to guidelines from the National Institutes
of Health and with an approved protocol from the Institutional
Animal Care and Use Committee of University of Nebraska
Medical Center (Permit Number: 10-015-05). The mice aged from
5 to 30 weeks were used for this study.
Cell culture and retroviral infection. B220+ cells were
isolated from bone marrow of IRF4
+/2Myc mice using a MACS
Figure 2. IRF4
+/2Myc leukemic cells were derived from large pre-B cells and were transplantable. A/B/) Bone marrow cells were isolated
from six-week old IRF4
+/2, IRF4
+/+Myc and IRF4
+/2Myc mice. The cells were stained with antibodies against CD43, Bp-1, CD19 and B220. The stained
cells were analyzed by FACS. Numbers are percentages of cells in the respective quadrant. C) IRF4
+/2Myc leukemic cells expressed intracellular m. The
bone marrow cells isolated above were stained with antibodies against B220 and CD43. After fixation and permeablization, the expression of
intracellular heavy chain m was detected with an anti-IgM antibody. The isotype IgG1 antibody staining was uses as a control for non-specific binding.
The dark area (control IgG1) and light area (anti-IgM). D) IRF4
+/2Myc cells expressed surrogate light chain l5. Bone marrow cells isolated from
IRF4+/2 and IRF4
+/2Myc mice were cultured in presence of IL-7 for two days. The expression of surrogate light chain l5 was detected by FACS. E)
Bone marrow cells were isolated from IRF4+/2Myc mice and transplanted into the non-irradiated syngenic host mice at 1610
6 cells per mice. A total
of 10 host mice were used. The host mice were analyzed by FACS after 5 to 10 weeks. A representative bone marrow analysis was shown.
doi:10.1371/journal.pone.0022628.g002
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on top of an irradiated S17 stromal cell layer in Opti-MEM
(Gibco) medium containing 5% FBS, 50 mM b-mercaptoethanol,
2 mM L-glutamine, 100 U penicillin-streptomycin and 5 ng/ml
IL-7 (R&D). S17 is a bone marrow stromal cell line that can
support both myeloid and B lymphocyte development. Retroviral
vectors expressing p27
kip have been described previously [7].
Retroviral infection of cultured IRF4
+/2Myc leukemic cells was
conducted as described previously [7]. The infected cells were
analyzed by FACS two days after infection.
Fluorescence-activated cell sorter analysis (FACS), TUNEL,
and cell cycle analyses
5–10 weeks old IRF4
+/+, IRF4
+/2, IRF4
+/+Myc and
IRF4
+/2Myc mice were used for FACS analysis. Cells were pre-
incubated with either 2% rat serum or Fc-Block (2.4G2), and
stained with optimal amounts of specific antibodies, either
biotinylated or directly fluorophore-conjugated. Antibodies against
B220 (RA3-6B2), CD19 (ID3), Thy-1, CD43, Bp-1, IgM and l5
were purchased from Pharmingen; FACS analysis was performed
with a FACS Calibur flow cytometer. The terminal deoxynucleo-
tidyltranferase-mediated dUTP-biotin nick end labeling (TUNEL)
assay was carried out with an APO-Direct Kit (Pharmingen). B
cells labeled with dUTP in the absence of terminal transferase
were used as negative control. The stained cells were analyzed by
FACS. Cell cycle analysis with live cells was conducted using
Hoechst 33342 dye as previously described [7].
Bone marrow transplantation
Bone marrows cells were isolated from hind limbs of the mice.
The whole bone marrow cells were injected via retro-orbital sinus
into nonirradiated syngenic host mice at 1610
6 cells per mice. B
cell population in the recipient mice was analyzed by FACS after
five to 10 weeks.
Western Blot and Immunohistochemistry analysis
Isolated B cells were lysed and used for Western blot analysis.
The signals were visualized using the SuperSignal West Dura
HRP Detection kit (Pierce). The information for the antibodies
Figure 3. B220+IgM2 cells in IRF4
+/2Myc mice exhibited
enhanced proliferation and reduced apoptosis. Bone marrow
cells were isolated from four-week old IRF4
+/2,I R F 4
+/+Myc and IRF4
+/2Myc
mice. The cells were stained with antibodies against B220 an IgM. A) To
analyze cell cycle status, the stained cells were incubated with Hoechst dye
(10 mg/ml) and analyze by LSR II Flow Cytometer. The percentages of
cycling cells among B220+IgM2 population in different groups were
shown. B) To detect apoptotic cells, the stained cells were fixed and
permeablized. The percentages of apoptotic cells among B220+IgM2
population were determined with a TUNEL kit and plotted as fold changes
over IRF4
+/2control mice. The results are average and standard deviation of
the values obtained from six independent experiments. * p,0.05; **
p,0.01.
doi:10.1371/journal.pone.0022628.g003
Figure 4. loss the expression of p27
kip and disruption of Arf-
p53 pathway in IRF4
+/2Myc leukemic cells. A) Bone marrow cells
were isolated from four-week old IRF4
+/+Myc (n=3) and IRF4
+/2Myc
mice (n=6). The B220+IgM2 population were isolated via sorting and
were lysed. Western blot analysis was carried out with antibodies
against p27, Myc and b-actin. B) IRF4
+/2Myc leukemic cells were
cultivated in RPMI-1640 plus 5% FBS in the presence of IL7 (5 ng/ml).
The cells were infected with retrovirus expressing either MigR1 (control)
or MigR1-p27 (p27). Two days after infection, the infected cells were
incubated with Hoechst dye and analyzed by LSR II Flow Cytometer.
The percentages of cycling cells in control and p27 infected cells were
shown. The results are average and standard deviation of the values
obtained from three independent experiments. ** p,0.01 C) leukemic
cells were isolated from twelve sick IRF4
+/2Myc mice and lysed for
Western blot analysis. The antibodies against p53, Arf, Myc and b-actin
were used.
doi:10.1371/journal.pone.0022628.g004
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kip, Myc and
b-actin (Santa Cruz); antibody against Arf (ab80, Abcam) and
antibody against p53 (Ab7, Calbiochem). For immunohistochem-
ical analysis, the spleens were fixed in formalin and paraffin-
embedded. H&E staining was carried out at the tissue process core
facility of the University of Nebraska Medical Center.
Generation of an inducible IRF4 transgenic mouse
To generate Doxycline (Dox) responsive IRF4 transgenic mice,
a full-length IRF4 cDNA with a HA tag at the N-terminus was
inserted into the pTet-Splice vector, generating the transgenic
plasmid (IRF4Tg). The expression of the IRF4 transgene is driven
by a TRE promoter which consists of a minimal CMV promoter
fused with a tetracycline response element. Microinjections were
performed by the Transgenic Mouse Core Facility at the
University of Nebraska Medical Center. Six different founder
lines were established and crossed with another transgenic line
which expresses tetracycline transactivator gene MMTV-tTA
mice (Jackson lab). In this system, tTA becomes active in the
absence but not in the presence of Dox. After crossing, all lines
were found to express IRF4 in the absence of Dox and the one
expressing the highest level of IRF4 was chosen for further
analysis. All mice were maintained under specific pathogen-free
conditions. Experiments were performed according to guidelines
from the National Institutes of Health and with an approved
protocol from the Institutional Animal Care and Use Committee
of University of Nebraska Medical Center (Permit Number: 10-
015-05). The mice aged from 5 to 30 weeks were used for this
study.
Supporting Information
Figure S1 Two additional sets of independent experi-
ments to show that c-Myc induced leukemia is acceler-
Figure 5. IRF4 functions as a tumor suppressor in c-Myc induced leukemia. A) IRF4+/2Myc leukemic cells lost the wild type IRF4 allele.
B220+IgM2 cells were isolated from bone marrow of sick IRF4
+/2Myc mice (n=6) and two IRF4
+/+Myc littermate control mice. The B220+IgM2 cells
were lysed for Western blot analysis with antibodies against IRF4, Myc and b-actin. B) Map of IRF4 transgenic construct. The diagram depicts the
constructs of IRF4 transgenic construct including tetracycline response element (TRE) and SV40 intron and ployA tail. C) IRF4 transgene was
predominantly expressed in B cells. IRF4Tg and MMTV-tTA single transgenic mice were crossed to generate double transgenic mice (Tg-tTA). B cells, T
cells and granulocytes were isolated from Tg-tTA double transgenic mice one week after Dox removal. The cells isolated from Tg-tTA mice fed with
Dox water were lysed and used as control. The expression of the IRF4 transgene was detected by Western Blot using an anti-HA antibody. D/E)
Expression of IRF4 transgene inhibited the expansion of IRF4
+/2Myc leukemic cells. The Tg-tTA transgenic mice crossed with IRF4 deficient mice and
EmMyc mice to generate IRF4
+/2 mice that were hemizygous for Tg-tTA and EmMyc transgene (IRF4
+/2MycTg-tTA). At five weeks of age,
IRF4
+/2MycTg-tTA mice were either switched to regular water to induce transgene expression or continuously fed with dox water. After another three
weeks, the mice were sacrificed and analyzed by FACS. Numbers of B220+IgM2 cells in the bone marrow of IRF4
+/2MycTg-tTA mice were counted
(D). In addition, percentages of cycling cells among B220+IgM2 population were also analyzed using method described above (E). The results were
averages and standard deviations of six independent experiments. *p,0.05. F) Expression of IRF4 transgene induced the expression of p27 in
IRF4
+/2Myc leukemic cells. B220+IgM2 cells were isolated from three pairs of IRF4
+/2MycTg-tTA mice in presence or absence of Dox and lysed for
Western blot analysis. The effect of IRF4 transgene expression on p27 expression was examined.
doi:10.1371/journal.pone.0022628.g005
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+/2Myc mice. A) splenomegaly in
IRF4
+/2Myc mice B) Spleens were isolated from IRF4
+/2,
IRF4
+/+Myc and IRF4
+/2Myc mice and paraffin-embedded for
H&E staining analysis. The stained tissues were examined under
both low (2.56) and high (106) magnifications. C/D/E). Cells
were isolated from the bone marrow (C), spleen (D) and blood (E)
of six-week old IRF4
+/2, IRF4
+/+Myc and IRF4
+/2Myc mice,
stained with indicated antibodies and analyzed by FACS.
Numbers indicated the percentages of cells in the respective
quadrant. CD11b+ myeloid cells in the bone marrow were
examined under a live cell gate while B and T cells were examined
under a lymphocyte gate. The data shown are representative of at
least three independent experiments.
(TIF)
Figure S2 Two additional sets of independent experi-
ments to show that IRF4
+/2Myc leukemic cells were
derived from large pre-B cells and were transplantable.
A/B/) Bone marrow cells were isolated from six-week old
IRF4
+/2, IRF4
+/+Myc and IRF4
+/2Myc mice. The cells were
stained with antibodies against CD43, Bp-1, CD19 and B220. The
stained cells were analyzed by FACS. Numbers are percentages of
cells in the respective quadrant. C) IRF4
+/2Myc leukemic cells
expressed intracellular m. The bone marrow cells isolated above
were stained with antibodies against B220 and CD43. After
fixation and permeablization, the expression of intracellular heavy
chain m was detected with an anti-IgM antibody. The isotype IgG1
antibody staining was uses as a control for non-specific binding.
The dark area (control IgG1) and light area (anti-IgM). D)
IRF4
+/2Myc cells expressed surrogate light chain l5. Bone
marrow cells isolated from IRF4+/2 and IRF4
+/2Myc mice were
cultured in presence of IL-7 for two days. The expression of
surrogate light chain l5 was detected by FACS. E) Bone marrow
cells were isolated from IRF4+/2Myc mice and transplanted into
the non-irradiated syngenic host mice at 1610
6 cells per mice. A
total of 10 host mice were used. The host mice were analyzed by
FACS after 5 to 10 weeks. Two representative bone marrow
analysis were shown.
(TIF)
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